Neurotech International Says Oral Toxicology Studies of NTI164 Drug Candidate Demonstrate No Safety Concerns
MT Newswires Live
May 05, 2025
Neurotech International (ASX:NTI) said the 28-day good laboratory practice oral toxicology studies in rats and dogs evaluating its NTI164 drug candidate demonstrated excellent tolerability and no safety concerns, according to a Monday Australian bourse filing.
The animals received twice-daily oral dosing across low, mid, and high dose levels, followed by a 14-day recovery period.
It said that no test article-related adverse effects were observed across clinical observations, ophthalmic exams, neurological assessments, or clinical pathology.
The firm is focused on treating paediatric neurological disorders via the NTI164 broad-spectrum oral cannabinoid drug therapy candidate.
Its shares rose 9% on Monday's close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.